The US pharmaceutical company Baxter International is to establish a new global innovation and R&D center for biopharmacetucals in Cambridge, Massachusetts, US. This follows Baxter's decision to hive off its biopharmaceutical business as an independent company called Baxalta in mid-2015.
The new R&D center will house 400 R&D staff, who will relocate from current sites in California and Europe, although Baxalta will retain certain R&D operations at its site in Vienna, Austria. In addition, the new center will house Baxalta's business development, oncology and biosimilars teams.